In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
Ann Intern Med
; 174(3): JC29, 2021 03.
Article
en En
| MEDLINE
| ID: mdl-33646835
SOURCE CITATION: Voysey M, Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99-111. 33306989.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vacunas
/
COVID-19
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Humans
País/Región como asunto:
Africa
/
America do sul
/
Brasil
/
Europa
Idioma:
En
Revista:
Ann Intern Med
Año:
2021
Tipo del documento:
Article